Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Gene Therapy is participating in a pilot of NISO/STM's Working Group on Peer Review Terminology. to identify and standardize definitions and terminology in peer review practices. Please see the section entitled Peer Review Terminology under the Guide for Authors, Editorial Process or For Referees for more information and to locate the link to complete the short survey.
Every month or so we will be featuring one of our editorial team, allowing them the opportunity to impart some of their wisdom and knowledge with you, our authors and readers, and you the opportunity to get to know them a little better. To kick it off we have our Editor-in-Chief, Janine Scholefield
One of the most exciting aspects emerging from the field of gene therapy is that it demonstrates how it can be applied to targeting cancer cells. As cancer is rarely a monogenic disease, this demonstrates the extraordinary reach that gene therapy applications have beyond their original use in addressing those orphan diseases many of us have worked on during our careers. The papers in this collection use standard AAV based delivery approaches, apply AI algorithms, and argue the pros and cons of genome engineering towards CAR-T treatments. This collection is a validation that basic science can be used to build on a greater foundation of scientific capital which can be applied to many aspects of human health.